BAM
EBS icon

Belpointe Asset Management’s Emergent Biosolutions EBS Stock Holding History

Belpointe Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-418
Closed -$4.33K – 1326
2023
Q1 		$4.33K Sell
418
-75
-15% -$907 ﹤0.01% 3068
2022
Q4 		$5.82K Buy
+493
New +$7.63K ﹤0.01% 2872
2021
Q4 		– Sell
-3,413
Closed -$161K – 1215
2021
Q3 		$161K Buy
3,413
+1,307
+62% +$79.1K 0.01% 949
2021
Q2 		$122K Buy
+2,106
New +$135K 0.01% 1040

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belpointe Asset Management's EBS Position: Q2 2023 in Review

Belpointe Asset Management sold out of Emergent Biosolutions (EBS) in Q2 2023, closing a stake of 418 shares — an estimated $4.33K sold.

Belpointe Asset Management first reported a position in EBS in Q2 2021 and held it in 4 quarters. The position peaked at $161K in Q3 2021. 183 funds tracked by Wall St. Rank hold EBS as of Q2 2023.

  • Belpointe Asset Management reported no remaining Emergent Biosolutions position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 418 Emergent Biosolutions shares in Q2 2023, an estimated $4.33K.
  • Belpointe Asset Management first reported a position in Emergent Biosolutions in Q2 2021 and held it in 4 quarters.
  • Belpointe Asset Management's Emergent Biosolutions position peaked at $161K in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.